trial

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

NCTId NCT04013555
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 88 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2024-08-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
88 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2020-01-20
Primary completion
2024-08-14
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
N-acetylcysteine (NAC)Tryptophan

Sponsors

University of Maryland, Baltimore CountyLead Sponsor

Investigators

1
Robert C Smith, M.D., Ph.DPrincipal Investigator

Sites

1 total
Catonsville, United States

Linked catalysts

1
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophren — primary completion2024-08-14

Facts & assertions

4 sourced
Enrollment
88
Phase
PHASE1,PHASE2
Primary Completion Date
2024-08-14
Status
COMPLETED
relationships
The graph out of here
drug
N-acetylcysteine (NAC)
drug
Tryptophan
drug
lead_sponsor
University of Maryland, Baltimore County
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Robert C Smith, M.D., Ph.D
person